Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment.

Journal article

Peer reviewed

Guillaume Cartron, Marc Ohresser, G. Salles, P. Solal-Celigny, P. Colombat, N. Varoqueaux and Hervé Watier

Annals of Oncology, Vol.19, pp.1485-1487

2008

Files and links (1)

url

Find in HALView

1 Record Views

Title: Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment.
Creators - without role: Guillaume Cartron - Service d'hématologie et oncologie médicale
Marc Ohresser - Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011]
G. Salles
P. Solal-Celigny
P. Colombat
N. Varoqueaux
Hervé Watier - Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011]
Publication Details: Annals of Oncology, Vol.19, pp.1485-1487
Identifiers: 9943885109311
Academic Unit: Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
Language: English
Resource Type: Journal article
Local Fields: hal-00317865